Daily pain in adults with sickle cell disease—a different perspective

American Journal of Hematology

Volumn 92, Issue 2, 2017, Pages 179-186

  van Tuijn, Charlotte F J ^a   Sins, Joep W R ^a,b   Fijnvandraat, Karin ^b   Biemond, Bart J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CODEINE; HYDROXYUREA; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PAIN; PAIN ASSESSMENT; PAIN INTENSITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; SICKLE CELL ANEMIA; ANALGESIA; ANEMIA, SICKLE CELL; COMPLICATION; PAIN MEASUREMENT; PAIN THRESHOLD; PREVALENCE; PROCEDURES; QUESTIONNAIRE; YOUNG ADULT;

ADULT; ANALGESICS; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYUREA; MALE; NETHERLANDS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PAIN THRESHOLD; PREVALENCE; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85009810464     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24612     Document Type: Article

References (53)

1. Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10:e1001484.
2. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle hemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013;381:142–151.
3. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood 2012;120:3647–3656.
4. McClish DK, Smith WR, Dahman BA, et al. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain 2009;145:246–251.
5. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325:11–16.
6. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317–1322.
7. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354–2363.
8. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79:17–25.
9. Manci EA, Culberson DE, Yang Y-M, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123:359–365.
10. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855–1865.
11. Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med. 1994;96:155–162.
12. Ballas SK. Update on pain management in sickle cell disease. Hemoglobin 2011;35:520–529.
13. Eaton ML, Haye JS, Armstrong FD, et al. Hospitalizations for painful episodes: association with school absenteeism and academic performance in children and adolescents with sickle cell anemia. Issues Compr Pediatr Nurs. 18:1–9.
14. Shapiro BS, Dinges DF, Orne EC, et al. Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance. Pain 1995;61:139–144.
15. van Tuijn C, van Beers E, Schnog J, et al. Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. Am J Hematol. 2010;85:532–535.
16. Gil KM, Carson JW, Porter LS, et al. Daily stress and mood and their association with pain, health-care use, and school activity in adolescents with sickle cell disease. J Pediatr Psychol. 28:363–373.
17. Fuggle P, Shand PA, Gill LJ, et al. Pain, quality of life, and coping in sickle cell disease. Arch Dis Child. 1996;75:199–203.
18. Dampier C, Lieff S, LeBeau P, et al. Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer 2010;55:485–494.
19. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148:94–101.
20. Westerman MP, Bailey K, Freels S, et al. Assessment of painful episode frequency in sickle-cell disease. Am J Hematol 1997;54:183–188.
21. Porter LS, Gil KM, Sedway JA, et al. Pain and stress in sickle cell disease: an analysis of daily pain records. Int J Behav Med. 1998;5:185–203.
22. Gil KM, Carson JW, Porter LS, et al. Daily mood and stress predict pain, health care use, and work activity in African American adults with sickle-cell disease. Health Psychol. 2004;23:267–274.
23. Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF. Arthritis Care Res. (Hoboken) 2011;63: S240–S252.
24. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277–299.
25. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129–138.
26. Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010;303:1288.
27. Porter LS, Gil KM, Carson JW, et al. The role of stress and mood in sickle cell disease pain: an analysis of daily diary data. J Health Psychol 2000;5:53–63.
28. Dampier C, Ely B, Brodecki D, et al. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain 2002;3:461–470.
29. Dampier C, Ely E, Brodecki D, et al. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. J Pediatr Hematol Oncol. 2002;24:643–647.
30. Dampier C, Ely B, Brodecki D, et al. Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease. Pediatr Blood Cancer 2014;61:291–296.
31. Anie KA, Dasgupta T, Ezenduka P, et al. A cross-cultural study of psychosocial aspects of sickle cell disease in the UK and Nigeria. Psychol Health Med. 2007;12:299–304.
32. Cabrita IZ, Mohammed A, Layton M, et al. The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. Br J Haematol. 2013;162:400–408.
33. Gladwin MT, Barst RJ, Gibbs JSR, et al. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One 2014;9:e99489.
34. Schimmel M, van Beers EJ, van Tuijn CFJ, et al. N-terminal pro-B-type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease. Am J Hematol. 2015;90:E75–E76.
35. Lê PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer 2015;62:1956–1961.
36. van der Plas EM, van den Tweel XW, Geskus RB, et al. Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening. Br J Haematol. 2011;155:106–110.
37. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 2007;92:905–912.
38. Schoen C, Doty M. Inequities in access to medical care in five countries: findings from the 2001 Commonwealth Fund International Health Policy Survey. Health Policy (New York) 2004;67:309–322.
39. Docteur E, Berenson RA. How does the quality of U.S. health care compare internationally? Timely Anal Immed Heal Policy Issues 2009:1–14.
40. Decker SL, Kostova D, Kenney GM, et al. Health status, risk factors, and medical conditions among persons enrolled in Medicaid vs uninsured low-income adults potentially eligible for Medicaid under the Affordable Care Act. JAMA 2013;309:2579–2586.
41. Fiscella K, Franks P, Gold MR, et al. Inequality in quality. JAMA 2000;283:2579.
42. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–248.
43. Ruta NS, Ballas SK. The opioid drug epidemic and sickle cell disease: guilt by association. Pain Med. 2016;17 [Epub ahead of print].
44. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans. Clin J Pain 2008;24:479–496.
45. Tewari S, Brousse V, Piel FB, et al. Environmental determinants of severity in sickle cell disease. Haematologica 2015;100:1108–1116.
46. Novelli EM, Gladwin MT. Crises in sickle cell disease. Chest 2016;149:1082–1093.
47. Bartolucci P, Habibi A, Khellaf M, et al. Score predicting acute chest syndrome during vaso-occlusive crises in adult sickle-cell disease patients. EBioMedicine 2016;10:305–311.
48. WHO. Cancer Pain Relief: With a Guide to Opioid Availability. 2nd ed. Geneva: WHO; 1996.
49. Hollins M, Stonerock GL, Kisaalita NR, et al. Detecting the emergence of chronic pain in sickle cell disease. J Pain Symptom Manage. 2012;43:1082–1093.
50. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am. 2005;19:785–802.
51. Paul R, Minniti CP, Nouraie M, et al. Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. Eur J Haematol. 2013;91:62–68.
52. Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89:530.
53. van Beers EJ, van Tuijn CFJ, Mac Gillavry MR, et al. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica 2008;93:757–760.